EGFR and non-small cell lung carcinoma: In a subgroup of phase II study KEYNOTE 021, when receiving a combination of ipilimumab and pembrolizumab, the ORR was 10% for EGFR-mutant NSCLC after TKIs resistance and 30% for the EGFR wild-type group.